BridgeBio Pharma (BBIO) Invested Capital: 2019-2025
Historic Invested Capital for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $74.3 million.
- BridgeBio Pharma's Invested Capital rose 106.09% to $74.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.3 million, marking a year-over-year increase of 106.09%. This contributed to the annual value of -$729.0 million for FY2024, which is 46.17% up from last year.
- According to the latest figures from Q3 2025, BridgeBio Pharma's Invested Capital is $74.3 million, which was up 104.15% from -$1.8 billion recorded in Q2 2025.
- In the past 5 years, BridgeBio Pharma's Invested Capital ranged from a high of $358.1 million in Q1 2021 and a low of -$1.8 billion during Q2 2025.
- For the 3-year period, BridgeBio Pharma's Invested Capital averaged around -$1.1 billion, with its median value being -$1.2 billion (2023).
- In the last 5 years, BridgeBio Pharma's Invested Capital slumped by 13,126.74% in 2022 and then skyrocketed by 106.09% in 2025.
- BridgeBio Pharma's Invested Capital (Quarterly) stood at -$867.0 million in 2021, then tumbled by 43.41% to -$1.2 billion in 2022, then declined by 8.92% to -$1.4 billion in 2023, then spiked by 46.17% to -$729.0 million in 2024, then surged by 106.09% to $74.3 million in 2025.
- Its Invested Capital stands at $74.3 million for Q3 2025, versus -$1.8 billion for Q2 2025 and -$1.6 billion for Q1 2025.